1. Home
  2. ZBAI vs ICCC Comparison

ZBAI vs ICCC Comparison

Compare ZBAI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZBAI

ATIF Holdings Limited Ordinary Shares

N/A

Current Price

$7.54

Market Cap

68.1M

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$7.97

Market Cap

64.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZBAI
ICCC
Founded
2015
1982
Country
United States
United States
Employees
6
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.1M
64.0M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
ZBAI
ICCC
Price
$7.54
$7.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.9K
23.1K
Earning Date
06-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
N/A
N/A
Revenue
N/A
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
51.64
52 Week Low
$0.30
$4.52
52 Week High
$11.94
$8.23

Technical Indicators

Market Signals
Indicator
ZBAI
ICCC
Relative Strength Index (RSI) 58.48 73.21
Support Level $5.86 $5.78
Resistance Level $9.56 N/A
Average True Range (ATR) 0.75 0.33
MACD 0.08 0.14
Stochastic Oscillator 72.57 87.88

Price Performance

Historical Comparison
ZBAI
ICCC

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: